Seeking Alpha

Raptor Pharmaceutical (RPTP +16%) surges to a new 52-week high today, after the company reported...

Raptor Pharmaceutical (RPTP +16%) surges to a new 52-week high today, after the company reported late yesterday that the FDA's Office of Orphan Product Development has granted seven-year orphan drug exclusivity for Procysbi delayed-release capsules for the management of nephropathic cystinosis. The exclusivity period began on the date of the drug's initial FDA approval, April 30.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs